tenapanor

Tenapanor is a small molecule inhibitor of the sodium/hydrogen exchanger isoform 3 (NHE3), primarily expressed on the apical surface of enterocytes in the small intestine and colon. By inhibiting NHE3, tenapanor reduces sodium absorption from the gut, leading to increased water retention in the intestinal lumen, softer stool consistency, and accelerated intestinal transit. It is approved for treating irritable bowel syndrome with constipation (IBS-C) and hyperphosphatemia associated with chronic kidney disease in adults on dialysis. Tenapanor also decreases visceral hypersensitivity and may reduce intestinal permeability by modulating tight junctions. The drug was developed by Ardelyx and is marketed under brand names including Ibsrela and Xphozah[1][2][4][5][6][7].

Brand names

IbsrelaXphozah

Other names

tenapanor hydrochloride